Meeting
2021 ASCO Annual Meeting
AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
Presenter
Lingying Wu, MD, PhD
Cancer Hospital, Chinese Academy of Medical Sciences
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04693234
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5595)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5595
Abstract #
TPS5595
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2012 ASCO Annual Meeting
Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Speaker: Prakash Varadarajan, MD
Videos & Slides
2024 ASCO Annual Meeting
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.
Speaker: Luis Manso, MD
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
Speaker: Jianqing Zhu, MD